SCHEMBL25815814

SCHEMBL25815814

CC(C)(C)OC(=O)NC1Cc2cnccc2N(c2ccc(C(F)(F)F)cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.39
FPR1 P21462 1/20 0.38
FPR2 P25090 1/20 0.38
ALDH1A1 P00352 1/20 0.36
GRM2 Q14416 2/20 0.35
GAA P10253 3/20 0.34
GPR119 Q8TDV5 1/20 0.34
PYGL P06737 1/20 0.34
PYGM P11217 1/20 0.34
MAPT P10636 1/20 0.34
ROCK2 O75116 1/20 0.34
SCN9A Q15858 1/20 0.34
BTK Q06187 1/20 0.34
CYP46A1 Q9Y6A2 1/20 0.33
CCR2 P41597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27057724 0.92 SLC6A2 (0.39) SLC6A2FPR1FPR2ALDH1A1GRM2
SCHEMBL25379854 0.87 FPR1 (0.41) SLC6A2FPR1FPR2ALDH1A1GRM2
SCHEMBL25815779 0.86 SLC6A2 (0.53) SLC6A2PYGLPYGMSCN9A
SCHEMBL25379814 0.83 TEAD1 (0.41) SLC6A2FPR1FPR2ALDH1A1GRM2
SCHEMBL30767958 0.83 SLC6A2 (0.39) SLC6A2FPR2GAAPYGLPYGM
SCHEMBL27057629 0.83 SLC6A2 (0.39) SLC6A2FPR2GAAPYGLPYGM
SCHEMBL27057711 0.81 SCN9A (0.40) SLC6A2FPR1FPR2PYGLPYGM
SCHEMBL27057694 0.81 SLC6A2 (0.39) SLC6A2FPR1FPR2GPR119SCN9A
SCHEMBL30767936 0.81 SLC6A2 (0.39) SLC6A2FPR1FPR2GPR119SCN9A
SCHEMBL30767979 0.80 EPHX2 (0.40) FPR1FPR2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378202-B2 Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2025-08-05 US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 US disclosed
US-20230278962-A1 Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-09-07 US disclosed
US-20230278962-A1 Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-09-07 US disclosed
WO-2023122781-A2 TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed
WO-2023122781-A2 TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER YAP1, TEAD2, TEAD1 SLC6A2 4362/4885FPR1 2283/4885FPR2 2286/4885
US-20230278962-A1 Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD2, TEAD4 SLC6A2 4206/4885FPR1 2737/4885FPR2 2268/4885
US-12378202-B2 Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD2, TEAD4 SLC6A2 4206/4885FPR1 2737/4885FPR2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.